Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tesaglitazar.

Niklaus Kamber1, Timothy M E Davis

  • 1University of Western Australia, School of Medicine and Pharmacology, Fremantle Hospital, Fremantle, WA 6959, Australia. nkamber@meddent.uwa.au

Idrugs : the Investigational Drugs Journal
|October 29, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The longitudinal relationship between carotid arterial disease and retinopathy complicating type 2 diabetes: The Fremantle diabetes study phase II.

Journal of diabetes and its complications·2026
Same author

Malaria in Papua New Guinean infants: a prespecified analysis of a randomised postpartum antimalarial treatment trial.

Transactions of the Royal Society of Tropical Medicine and Hygiene·2026
Same author

Refining insights on type 2 diabetes and aortic valve replacement-reply to Liu et al.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same author

Incidence and associates of aortic valve replacement in people with or without type 2 diabetes: The Fremantle diabetes study phase II.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same author

Prognostic value of a plasma protein-based biomarker test for chronic kidney disease complicating diabetes in Aboriginal Australians.

Internal medicine journal·2025
Same author

Assessment of biomarkers associated with renal decline for prediction of incident distal sensory polyneuropathy in type 2 diabetes.

Scientific reports·2025
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Tesaglitazar, an oral dual peroxisome proliferator-activated receptor alpha/gamma agonist, is being developed to improve lipid levels and blood sugar in type 2 diabetes. This drug targets both dyslipidemia and glycemic control for diabetic patients.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Dyslipidemia and glycemic control are critical challenges in managing type 2 diabetes.
  • Peroxisome proliferator-activated receptors (PPARs) play a key role in regulating lipid and glucose metabolism.

Purpose of the Study:

  • To evaluate the potential of tesaglitazar, a dual PPARα/γ agonist, in improving dyslipidemia and glycemic control.
  • To assess the therapeutic efficacy of tesaglitazar in patients with type 2 diabetes.

Main Methods:

  • Development of tesaglitazar, an oral dual PPARα/γ agonist.
  • Investigating the drug's effects on lipid profiles and blood glucose levels.

Main Results:

  • Tesaglitazar demonstrates potential for improving dyslipidemia.

Related Experiment Videos

  • The drug shows promise in enhancing glycemic control in type 2 diabetic patients.

    • Conclusions:

    • Tesaglitazar represents a potential therapeutic option for managing type 2 diabetes comorbidities.
    • Dual PPARα/γ agonism offers a promising strategy for addressing both lipid and glucose abnormalities.